Most Read Articles
3 days ago
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
Tristan Manalac, Yesterday
Major depressive disorder (MDD) appears to be more prevalent in females than in males, particularly in those who are divorced or widowed, a recent study from Singapore has found.
6 days ago
Cognitive deficits in bipolar disorder are neurodevelopmental rather than neurodegenerative in nature, a recent study has reported. Furthermore, cognitive impairment in bipolar patients appears to be stable, in the majority at least.
2 days ago
Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.

Scarce information comparing treatments for HA and RES RRMS

18 Mar 2017
Multiple Sclerosis (MS) is a debilitating disease, in which nerve damage affects communications between the brain and body. HSCT could provide the therapeutic answer for MS patients.

There is a shortage of information comparing the efficacy of treatments for patients with highly active (HA) and rapidly evolving severe (RES) relapsing-remitting multiple sclerosis (RRMS), resulting in low-confidence conclusions, a new systematic literature review reveals.

The present review accessed the databases of The Cochrane Library, Embase and Medline, the US Food and Drug Administration, ClinicalTrials.gov and the European Medicines Agency. Studies that investigated treatments for HA or RES RRMS recommended for reimbursements in the UK were included.

A Bayesian network meta-analysis (NMA) was performed on the collected data to determine the efficacy of fingolimod vs dimethyl fumarate (DMF) for HA RRMS vs natalizumab for RES RRMS.

After applying the inclusion and exclusion criteria, the review yielded 8 studies eligible for inclusion: four on RES RRMS and five on HA RRMS (one study reported on both). Of these, only two for HA RRMS and three for RES RRMS had adequate patient subgroup data for NMA.

The network for HA RRMS associated fingolimod with DMF via placebo as the common comparator. Both fingolimod and DMF produced significant improvements over 3 months. However, there was no significant difference between fingolimod and DMF.

In the network for RES RRMS, fingolimod was associated with natalizumab through placebo. Similarly, both treatments yielded significant improvements over placebo but not over each other.

More importantly, the systematic literature review and subsequent NMA revealed the lack of existing data and information comparing treatments between multiple sclerosis patient subgroups. This may impose important limitations in creating recommendations for clinical guidelines.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 days ago
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
Tristan Manalac, Yesterday
Major depressive disorder (MDD) appears to be more prevalent in females than in males, particularly in those who are divorced or widowed, a recent study from Singapore has found.
6 days ago
Cognitive deficits in bipolar disorder are neurodevelopmental rather than neurodegenerative in nature, a recent study has reported. Furthermore, cognitive impairment in bipolar patients appears to be stable, in the majority at least.
2 days ago
Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.